FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.
What happened
FDA reviewed JulyMD's website at https://julymd.com in August 2025. It found the site offered compounded drug products, including semaglutide, and claimed the compounded semaglutide had the same active ingredient as Wegovy and Ozempic at a fraction of the price. FDA said compounded drugs are not FDA-approved, so these claims are false or misleading and make the products misbranded.
What FDA found
The website claimed compounded semaglutide had the same active ingredient as Wegovy and Ozempic and was an affordable alternative, implying the compounded product was the same as FDA-approved drugs.
FDCA section 502(a) [21 U.S.C. § 352(a)]The website's advertising and promotion of compounded semaglutide were false or misleading for making those equivalence claims even though compounded drugs are not FDA-approved.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]The misbranded compounded semaglutide products were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA tells JulyMD to take immediate action, including ceasing the misleading claims, and to respond in writing within 15 working days to CDER's Office of Compounding Quality and Compliance with the steps taken, how recurrence will be prevented, and supporting documentation.
Who should pay attention
- telehealth and online pharmacies selling compounded semaglutide
- compounding pharmacies and marketers comparing products to FDA-approved GLP-1 drugs
- platforms or brands hosting or promoting compounded drug offers
This is a summary. Read the original letter on fda.gov.